Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

NCT02311361 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

65

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Neoplasms
Pancreatic Cancer
Cancer of Pancreas
Cancer of the Pancreas
Pancreas Cancer

Interventions

BIOLOGICAL: Durvalumab
BIOLOGICAL: Tremelimumab
RADIATION: Sterostatic body radiation therapy (SBRT)

Sponsor

National Cancer Institute (NCI)